Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms and QofL for GPP Patients
Spesolimab-sbzo (Spevigo, Boehringer Ingelheim) improves physical symptoms and lessens the mental health burden associated with generalized pustular psoriasis (GPP), according to post-hoc exploratory analyses from the EFFISAYIL 2 clinical trial. The data were presented at the 2025 American Academy of Dermatology’s annual meeting in Orlando, FL. In EFFISAYIL 2, patients with a history of GPP […]